Compound class:
Synthetic organic
Comment: Compound 4d is reported as an irreversible, non-peptide inhibitor of kallikrein proteins [3]. This compound appears to be patent protected by US-9006466-B2 [2].
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
References |
1. Chavanas S, Bodemer C, Rochat A, Hamel-Teillac D, Ali M, Irvine AD, Bonafé JL, Wilkinson J, Taïeb A, Barrandon Y et al.. (2000)
Mutations in SPINK5, encoding a serine protease inhibitor, cause Netherton syndrome. Nat Genet, 25 (2): 141-2. [PMID:10835624] |
2. Reboud-Ravaux M, Amri CY-El, Tan X, Qin L, Pagano M, Hovnanian A, Furio , Pirotte B. (2015)
Use of coumarin derivatives for the preparation of drugs for treating skin diseases. Patent number: US 9,006,466 B2. Assignee: Universite Pierre et Marie Curie, Universite de Liege.. Priority date: 15/01/2014. Publication date: 14/04/2015. |
3. Tan X, Soualmia F, Furio L, Renard JF, Kempen I, Qin L, Pagano M, Pirotte B, El Amri C, Hovnanian A et al.. (2015)
Toward the first class of suicide inhibitors of kallikreins involved in skin diseases. J Med Chem, 58 (2): 598-612. [PMID:25489658] |